We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of BioSpecifics Technologies Corp. (“BSTC” or the “Company”) (NASDAQ: BSTC) in connection with the proposed acquisition of the Company by Endo International plc.  Under the terms of the acquisition agreement, which is structured as a tender offer, BSTC shareholders will receive $88.50 per share in cash for each share of BSTC that they hold.

WeissLaw is investigating whether BSTC’s board acted in the best interest of the Company’s public shareholders in agreeing to the proposed transaction, whether the per-share cash consideration reflects fair compensation for BSTC shareholders, and whether all information regarding the sales process and valuation of the transaction is  fully and fairly disclosed to BSTC stockholders.\n\nWeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com